• Sung Ran Kim, Hyeon Jeong Kang, Hye Rin Jeong, Su Yeon Jang, Jae Eun Lee, Da Eun Kim, Hae Ry Lee, Min Hee Cho, Ji Yun Noh, Hee Jin Cheong, Woo Joo Kim, and Joon Young Song.
• Infection Control Team, Korea University Guro Hospital, Seoul, Korea.
• J. Korean Med. Sci. 2022 Sep 5; 37 (35): e267e267.

AbstractThe omicron variant of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is known to have high infectivity and is more likely to evade vaccine immunity. However, booster vaccination is expected to strengthen cross-reactive immunity, thereby increasing the vaccine effectiveness (VE). This study aimed to evaluate the relative VE of the 3-dose (booster) vaccination compared with the 2-dose primary series vaccination in healthcare workers during omicron variant-dominant periods. During the omicron-dominant period from February 1, 2022 to February 28, 2022, a 1:1 matched case-control study was conducted. Healthcare workers with positive SARS-CoV-2 test results were classified as positive cases, whereas those with negative results served as controls. Compared with the 2-dose primary series vaccination, booster vaccination with mRNA vaccine showed moderate VE (53.1%). However, in multivariate analysis including the time elapsed after vaccination, the significant VE disappeared, reflecting the impact of recent vaccination rather than the third dose itself.© 2022 The Korean Academy of Medical Sciences.

14 keywords...

hide…